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Abstract: Background: Vitiligo is a common depigmentary disorder characterized by white patches of the skin, hair and 
mucous membranes due to selective destruction of melanocytes. 
Objective: The objective of this study was to analyze the clinical characteristics, coexisting diseases, presence of 
autoantibodies and autoimmune polyglandular syndrome (APS) in Estonian adult vitiligo patients. 
Methods:Adult patients with vitiligo were called to participate in the study at the Dermatology Department of Tartu 
University from January 2005 to July 2008. One hundred fifty five subjects were examined in 141 of those the level of 
thyroid peroxidase antibodies (TPO-Ab), gastric parietal cell antibodies (PCA), antinuclear antibodies (ANA), anti-
adrenal cortex antibodies (AAA) and rheumatoid factor (RF) in blood were measured. 
Results: Study group (mean age 44.9 years, mean age of vitiligo onset 28.5 years, mean duration of vitiligo 16.9 years) 
consisted of 44 males and 111 females. Vitiligo vulgaris was the most common clinical type (81.3%), followed by 
acrofacial, focal, segmental and universal vitiligo. Two-thirds of subjects reported a coexisting disease and 36.7% had one 
or more disease of autoimmune origin. The presence of autoantibodies was established in 49.6%. TPO-Ab was found in 
36.9%, PCA in 14.2%, ANA and AAA both in 2.8% and positive RF in 7.8% cases. 17 subjects had APS 3, 35 had 
subclinical APS 3 and two subjects had APS 4. 
Conclusions: Vitiligo vulgaris was the most frequent clinical type. Vitiligo was associated with other autoimmune 
diseases, the presence of autoantibodies in the blood was frequent (especially TPO-Ab) and many subjects had APS. 
Keywords: Vitiligo, clinical types, coexisting disease, autoantibodies, autoimmune polyglandular syndrome. 
INTRODUCTION 
 Vitiligo is a common acquired depigmentary disorder 
characterized by white patches of the skin, hair and mucous 
membranes due to selective destruction of melanocytes.
 
It 
affects 0.5-1% of the worldwide population and ranges up 
8.8% in India [1, 2].
 
Recent publications from China have 
shown that these numbers could be overestimated as they 
have found the prevalence of vitiligo to be 0.09-0.19% [3, 4] 
 In most cases disease appears before the age of 20 but it 
can start after fifty [5, 6]. There is still no uniform 
understanding of vitiligo clinical subtypes. Koga divides 
vitiligo into nonsegmental (A) and segmental (B) types 
based on the different distribution pattern and clinical course 
[7]. Hann and Nordlund created more complicated 
classification of vitiligo. According to the pattern of 
distribution they differentiated disease as localized, 
generalized and universal. Localized vitiligo can further  
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divide into focal (one or a few macules in nondermatomal 
distribution), segmental (one or more macules in dermatomal 
distribution), mucosal (depigmentation of lips, oral mucosa 
and genitals) and generalized vitiligo divides into acrofacial 
(distal parts of the extremities and face), vulgaris (scattered 
macules all over the body) and mixed (different types at the 
same time) types [8]. In universal type nearly complete or 
complete depigmentation of the skin appears.
 
The clinical 
phenotype of vitiligo can be changed during the years [9, 
10]. 
 Based on autoimmune hypothesis there are several 
studies focused on associated diseases in vitiligo patients and 
their families. Alkhateeb has found the elevation of several 
autoimmune disorders: vitiligo itself, thyroiditis, pernicious 
anemia, Addison’s disease, systemic lupus erythematosus 
and inflammatory bowel disease [11]. Other investigators 
have added to this list diabetes, rheumatoid arthritis, alopecia 
areata, psoriasis, chronic urticaria, asthma [12-14]. Results 
of the studies from different geographical regions are still 
controversial and needs clarification. Vitiligo is a part of 
autoimmune polyglandular syndromes (APS), most 
frequently of APS-3 (coexisting with autoimmune thyroid 
diseases) [15, 16]. 
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 The objective of this study was to present the clinical 
characteristics, coexisting diseases, presence of 
autoantibodies and APS in Estonian adult vitiligo patients. 
MATERIALS AND METHODOLOGY 
 Estonia is a small Baltic state with a population 1.4 
million people. Adult patients with vitiligo were called to 
participate in the study all over the country. The data were 
collected from January 2005 to July 2008. The study was 
approved by the Ethical Review Committee on Human 
Research of the University of Tartu and all participants 
signed a written informed consent. 
 Patients were examined at the Dermatology Department 
of Tartu University by an experienced dermatologist. The 
questionnaire, including age, sex, nationality, skin 
phototype, site of onset of vitiligo, duration, concomitant 
diseases, familial history, spontaneous repigmentation, 
previous treatment, was completed by a dermatologist. The 
diagnosis of vitiligo was based on characteristic loss of skin 
pigmentation with typical localization and the examination 
under Wood’s lamp. The clinical types of vitiligo were 
classified as focal (one or few macules in a nondermatomal 
distribution), segmental (unilateral segmental distribution), 
acrofacial (distal extremities and face), vulgaris (scattered 
over the body), universal (over 90% depigmentation). The 
presence of leukotrichia, Koebner phenomenon, and halo 
nevi was noted. The evolution of vitiligo considered active 
when new lesions appeared and existing lesions increased in 
size over the past 3 months. Vitiligo was stable when 
depigmentation did not increase during the last 3 months. 
 Antinuclear antibodies (ANA), gastric parietal cell 
antibodies (PCA) and anti-adrenal cortex antibodies (AAA) 
were determined by indirect immunofluorescence method 
using rat liver as antigenic substrate for ANA and mouse 
stomach as antigenic substrate for detection of PCA. AAA 
was detected on normal human adrenal tissue
 
[17, 18]. 
Polyclonal rabbit anti-human
 
IgG conjugated to fluorescein 
isothiocyanate (DAKO, Glostrup, Denmark) was used as 
secondary antibody for detection of all these antibodies. 
CLIA, Immulite 2000 (Siemens Medical Solutions 
Diagnostics) was used for the detection of thyroid peroxidase 
antibodies (TPO-Ab) and immunoturbidimetric assay, Cobas 
Integra 400 Plus (Roche Diagnostics GmbH) for the 
assessment of rheumatoid factor (RF) [19]. 
RESULTS 
 In total, 155 patients, 44 males (28.4%) and 111 females 
(71.6%), were enrolled. The mean age of patients was 44.9 
years (age range 18 – 82years) and the mean age of vitiligo 
onset was 28.5 years (age range 2-76 years). The mean ages 
of onset for males and for females were 28.2 and 28.6, 
respectively. The mean duration of vitiligo was 16.9 years 
(0.5 -58 years) for all patients, 16.2 years for males and 17.2 
years for females. 51 subjects (32.9%) had skin phototype II, 
102 subjects (65.8%) had skin phototype III and 2 subjects 
(1.3%) had skin phototype IV. 
 Vitiligo vulgaris was the most common clinical type, 
observed in 126 cases (81.3%), followed by acrofacial, focal, 
segmental and universal vitiligo. Patients with segmental and 
universal vitiligo were affected earlier than other types of 
vitiligo (Table 1). 
Table 1. Comparisons of Mean Ages of Onset of Different 
Types of Vitiligo 
 
Clinical Types Vitiligo Number (%) Mean Age (y) of Onset 
Vulgaris 
Universal 
Acrofacial 
Segmental 
Focal 
Total 
126 (81.3) 
5 (3.2) 
12 (7.7) 
5 (3.2) 
7 (4.5) 
155 (100) 
28.0 
14.6 
44.2 
7.6 
34.7 
28.5 
 
 The most common site of onset vitiligo was the upper 
limb in 55 patients (35.5%), followed by trunk in 37(23.9%), 
lower limb in 27 (17.4%), head and neck in 23 (14.8%), 
body folds in 13 (8.4%) patients. Twenty patients (12.9%) 
showed Koebner’s phenomenon. Disease was active and 
progressed in 109 (70.3%) subjects, who confirmed the 
appearance of new lesions or increase in the size of existing 
lesions within the past 3 months. 
 At the time of the study, vitiligo initial clinical type had 
been transformed in 23 cases (14.8 %). Vitiligo vulgaris was 
the initial clinical type of 113 subjects (72.9%); five of them 
developed universal vitiligo. 12 cases of focal vitiligo and 6 
cases of acrofacial vitiligo transformed to vitiligo vulgaris. 
Segmental vitiligo did not transform to other subtype. 
 According to the extent of depigmentation, patients with 
minimal disease predominated. In 82 cases (52.9%) up to 
10% body surface area was involved. Hair depigmentation in 
vitiligo lesions were seen in 75 cases (48.4%) and mucosal 
involvement in 14 cases (9.0%). 
 60 subjects (38.7%) named factors that had brought on 
their vitiligo initially or worsened it. These were mechanical 
injury in 15 cases, psychological trauma in 15 cases, 
hormonal changes in 13 cases, sunburn in 6 cases, UV 
radiation and radiation in 6 cases, skin irritation in 3 cases, 
drug intake in 3 cases, and other disease in one case. 54 
patients (34.8%) had got some kind of treatment but without 
good effect. 43 subjects (27.7%) had noticed partial unstable 
spontaneous repigmentation in some of their lesions during 
the course of vitiligo. 
 In all, 104 patients (67.1%) self-reported a coexisting 
disease and 57 of those (36.7%) had one ore more disease of 
autoimmune origin. Halo nevi were seen in 24 cases 
(15.5%). 26 subjects (16.8%) gave a personal history of 
thyroid disease, 20 of them had been diagnosed autoimmune 
thyroiditis. Other coexisting diseases were hypertonia in 24 
cases, allergic conditions in 36 cases, psoriasis in 7 cases, 
rheumatoid arthritis and diabetes both in 6 cases, oncological 
and hematological diseases in 8 cases, alopecia areata, 
ancylosing spondylitis and pernicious anemia all in 2 cases 
(Table 2). 
 The same diseases could be found in their first and 
second degree relatives. 40 patients (26.0%) gave a family 
history of vitiligo, 32 (20.8%) of thyroid disease, 21 (13.6%) 
of diabetes, 13 (8.4%) of psoriasis, 7 (4.5%) of rheumatoid 
arthritis, 53 (34.4%) of hypertonia (Table 2). One subject did 
not know her relatives. 
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 The levels of TPO-Ab, PCA, ANA, AAA and RF in 
blood were measured of 141 subjects. The presence of 
autoantibodies was established in 70 cases. TPO-Ab were 
found in 52 subjects, PCA in 20 subjects, ANA and AAA 
both in 4 subjects and 11 had positive for RF. Concurring 
positivity of TPO-Ab and PCA was found in 12 cases; TPO-
Ab and AAA in two cases, TPO-Ab and RF in one case. 
Blood of one subject was positive for four measured 
antibodies (Table 3). 
Table 3. The Presence of Autoantibodies in the Blood 
 
Autoantibodies Type No. of Subjects (%) 
TPO-Ab 
PCA 
AAA 
ANA 
RF 
TPO-Ab and PCA 
TPO-Ab and AAA 
TPO-Ab and RF 
TPO-Ab, PCA, AAA, ANA 
52 (36.9) 
20 (14.2) 
4 (2.8) 
4 (2.8) 
11 (7.8) 
12 (8.5) 
2 (1.4) 
1 (0.7) 
1 (0.7) 
 
 According to the results of autoantibodies and the list of 
coexisting disorders we found that 17 subjects had APS 3, 35 
had subclinical APS 3 and two subjects had APS 4 (Table 4). 
DISCUSSION 
 Vitiligo affects both sexes equally, but some studies have 
shown the female preponderance [20, 21].
 
Our study group 
consisted of II and III skin phototype European Caucasians 
where females dominated (2.5:1) and the reason of this 
superiority can be the concern of cosmetic looks by the 
women. This extra-organized study for the adults showed 
older mean age of the subjects (44.9 years) and long-lasting 
disease (up to 58 years) comparing to the other studies [2, 
22]. Our data confirmed that the peak incidence of vitiligo is 
in the second or third decade of life
 
[23, 24].
 
In 38.7% of 
cases vitiligo appeared at the age of 20 and in 58.7% of cases 
at the age of 30. In 14.8% of cases vitiligo started after fifties 
and this was higher then 6.8% reported by Dogra [6]. The 
mean age of onset was same for the males and females. 
 Vitiligo vulgaris was the most common clinical type, 
observed in 81.3% of cases, followed by acrofacial, focal, 
segmental and universal vitiligo in descending order by 
frequency. Vitiligo vulgaris has been the most frequent 
clinical pattern in many published papers comprising in 39-
83% of subjects with vitiligo [2, 6, 9, 25]. We did not see 
local mucosal type and mixed vitiligo in our subjects. 
Segmental vitiligo was rare in our adult group and has been 
previously reported 0 – 4.5% in adults [6, 25]. We did not 
see segmental pattern in the face region, shown by Hann as 
the most frequent localisation in Korean patients [26]. The 
initial site of vitiligo was the upper limbs in one-third of the 
subjects, followed by the trunk, lower limbs, head and neck, 
body folds. Previous studies have found vitiligo initial sites 
to be limbs and face [2, 27, 28]. All these localizations are 
trauma - prone sites. Koebner’s sign stayed between 5-30% 
described by the others
 
[29, 30]. The number of subjects with 
leucotrichia was high, similar to Indian patients shown by 
Dogra and Dave [6, 31]. We got an opposite results of 
mucosal involvement. Only 9% of subjects had additional 
mucosal depigmentation.
 
Others have observed mucosal 
involvement between 7.4 - 74% [24, 29]. 
 Vitiligo was active in 70.3% of the subjects, similar 
results have published by Dave and Arycan [27, 31]. In spite 
of the long mean duration of vitiligo (16.9 years), subjects 
Table 2. Vitiligo Associated Diseases 
 
Associated Diseases Number of Vitiligo Subjects No of Vitiligo Subjects whose Relatives has the Disease 
Halo nevus  
Thyroid disease 
Diabetes 
Rheumatoid arthritis  
Psoriasis 
Gastroduodenal ulcer 
Pernicious anemia 
Alopecia areata 
Ankylosing spondylitis  
Multiplex sclerosis  
Sclerodermia 
Neurofibromatosis 
Addison disease 
Urticaria 
Fast type allergy (hair, dust, pollen) 
Asthma 
Atopic dermatitis 
Drug allergy 
Oncological and hematological disease 
Hypertonia  
24 
28 
6 
6 
7 
2 
2 
2 
2 
1 
1 
1 
0 
8 
7 
5 
2 
14 
8 
24 
 2 
31 
21 
7 
13 
0 
0 
2 
0 
0 
1 
0 
1 
0 
1 
3 
0 
0 
3 
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with minimal extension predominated. More than half of 
cases had up to 10% body surface area involvement; 
additional 32.9% had skin involvement between 11% and 
50%. Approximately three- quarters of the subjects reported 
that vitiligo had started as a vulgar clinical type and acquired 
symmetrical distribution during one-two years. Handa has 
shown vitiligo vulgaris approximately 70% of the subjects 
with average disease duration only 3.7 years
 
[2]. Contrary to 
Liu, who found the initial clinical type to be focal vitiligo in 
three - quarters in his study group, only in 12.3% of cases 
focal vitiligo was reported as onset type of vitiligo in our 
subjects [9]. Several studies have shown earliest onset of 
segmental vitiligo and we agree with this [26, 32]. Subjects 
with segmental and universal vitiligo were affected earlier 
than other types of vitiligo. Universal vitiligo showed a long-
lasting course with an average 30.8 years, but mean 
durability of focal vitiligo was only 4.6 years. It confirms the 
opinion that the disease has a slowly progressive and chronic 
long course. 
 Two-thirds of the subjects reported coexisting diseases 
and every third patient had diagnosed at least one disease of 
autoimmune origin, including halo nevi. We saw halo nevi in 
15.5% of cases, mostly one-two but in two patients 
numerously. In 9 cases of vitiligo, including these two, halo 
nevi were the first depigmented lesions on the skin before 
vitiligo appeared. Studies have shown the presence of halo 
nevi in 1-35% of vitiligo patients but seldom in adults [22, 
33]. Autoimmune thyroiditis has been the most frequent 
disease, associated up to 34% of vitiligo patients in different 
studies around the world, except in China
 
[13, 25, 34].
 
In our 
study 16.8% of the subjects gave a personal history of 
thyroid disease and 12.9 % were aware of autoimmune 
thyroiditis, having APS-3C. Studies from India and Nigeria 
showed lower (0.5-0.6%) incidence of thyroid disease 
because the screening was done only patients with clinical 
features [2, 25]. The number of subjects having vitiligo in 
their relatives was quite high (26.0%) as the positive family 
incidences stay between 10-36% [22, 35]. The prevalence of 
thyroid disease (20.1%), diabetes (13.5%), psoriasis (8.4%) 
and rheumatoid arthritis (4.5%) among the relatives in our 
study was high too, as already shown by the others
 
[12-14]. 
 The presence of measured autoantibodies was established 
in 49.6% of our adult group. The level of TPO-Ab in the 
blood was raised in 52 subjects, 35 of them were without 
clinical signs of thyroid disease and had not been checked 
before. As the TPO-Ab is the hallmark of autoimmune 
thyroiditis, we can assume that these 35 subjects had 
subclinical autoimmune thyroid disease and they belong to 
type APS-3C. According to the new APS classification by 
Betterle we discovered that one subject had APS-3 C+A, 
three had APS-3 D+C and two had APS-4
 
[15, 16]. Subjects 
with positive AAA and TPO-Ab needed further consultation 
suspected as having APS-2 (Addison disease and 
autoimmune thyroiditis). The elevation of rheumatoid factor 
was mild in 10 cases, except one subject with very high 
value and undiagnosed rheumatoid arthritis. 
CONCLUSION 
 Our study affirmed several well-known and some new 
aspects of vitiligo. Vitiligo vulgaris was the most frequent 
clinical type. Disease had long-lasting course with a slow 
progression during the years as absolute majority showed 
pigment loss less then 10% of body area. Vitiligo was 
associated with other autoimmune diseases, the presence of 
autoantibodies in the blood was frequent (especially TPO-
Ab) and many subjects had APS. 
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